Carboxypeptidase N: A pleiotropic regulator of inflammation

Molecular Immunology

Volumn 40, Issue 11, 2004, Pages 785-793

  Matthews, Kirstin W ^a,b   Mueller Ortiz, Stacey L ^a   Wetsel, Rick A ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Carboxypeptidase; Complement anaphylatoxins; Zinc metalloprotease

Indexed keywords

ANAPHYLATOXIN; ARGININE; ARGININE CARBOXYPEPTIDASE; BRADYKININ; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; CREATINE KINASE; KININ; LYSINE; NITRIC OXIDE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVE SITE; ENZYME DEGRADATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBUNIT; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; RECEPTOR BINDING;

EID: 0346849668     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2003.10.002     Document Type: Article

References (73)

1. Abendschein D.R., Morelli R.L., Carlson C.J., Emilson B., Rapaport E. Creatine kinase MM isoenzyme subforms in myocardium, cardiac lymph and blood after coronary artery occlusion in dogs. Cardiovasc. Res. 18:1984;690-696.
2. Abendschein D.R., Serota H., Plummer T.H. Jr., Amiraian K., Strauss A.W., Sobel B.E., Jaffe A.S. Conversion of MM creatine kinase isoforms in human plasma by carboxypeptidase N. J. Lab. Clin. Med. 110:1987;798-806.
3. Aloy P., Companys V., Vendrell J., Aviles F.X., Fricker L.D., Coll M., Gomis-Ruth F.X. The crystal structure of the inhibitor-complexed carboxypeptidase D domain II and the modeling of regulatory carboxypeptidases. J. Biol. Chem. 276:2001;16177-16184.
4. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler. Thromb. Vasc. Biol. 20:2000;2511-2518.
5. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J. Biol. Chem. 270:1995;14477-14484.
6. Bektas A., Hughes J.N., Warram J.H., Krolewski A.S., Doria A. Type 2 diabetes locus on 12q15. Further mapping and mutation screening of two candidate genes. Diabetes. 50:2001;204-208.
7. Boffa M.B., Reid T.S., Joo E., Nesheim M.E., Koschinsky M.L. Characterization of the gene encoding human TAFI (thrombin-activatable fibrinolysis inhibitor plasma procarboxypeptidase B). Biochemistry. 38:1999;6547-6558.
8. Bokisch V.A., Müller-Eberhard H.J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49:1970;2427-2436.
9. Cain S.A., Monk P.N. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J. Biol. Chem. 277:2002;7165-7169.
10. Campbell W., Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem. Biophys. Res. Commun. 162:1989;933-939.
11. Campbell W., Okada N., Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol. Rev. 180:2001;162-167.
12. Campbell W.D., Lazoura E., Okada N., Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol. Immunol. 46:2002;131-134.
13. Cao H., Hegele R.A. DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency. J. Hum. Genet. 48:2003;20-22.
14. Christianson D.W., Mangani S., Shoham G., Lipscomb W.N. Binding of D-phenylalanine and D-tyrosine to carboxypeptidase A. J. Biol. Chem. 264:1989;12849-12853.
15. Clauser E., Gardell S.J., Craik C.S., MacDonald R.J., Rutter W.J. Structural characterization of the rat carboxypeptidase A1 and B genes. Comparative analysis of the rat carboxypeptidase gene family. J. Biol. Chem. 263:1988;17837-17845.
16. Couture R., Harrisson M., Vianna R.M., Cloutier F. Kinin receptors in pain and inflammation. Eur. J. Pharmacol. 429:2001;161-176.
17. Deddish P.A., Skidgel R.A., Kriho V.B., Li X.Y., Becker R.P., Erdos E.G. Carboxypeptidase M in Madin-Darby canine kidney cells. Evidence that carboxypeptidase M has a phosphatidylinositol glycan anchor. J. Biol. Chem. 265:1990;15083-15089.
18. Devries S.R., Sobel B.E., Abendschein D.R. Early detection of myocardial reperfusion by assay of plasma MM-creatine kinase isoforms in dogs. Circulation. 74:1986;567-572.
19. Drouin S.M., Kildsgaard J., Haviland J., Zabner J., Jia H.P., McCray P.B. Jr., Tack B.F., Wetsel R.A. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J. Immunol. 166:2001;2025-2032.
20. Eaton D.L., Malloy B.E., Tsai S.P., Henzel W., Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 266:1991;21833-21838.
21. Ember, J.A., Jagels, M.A., Hugli, T.E., 1998. Characterization of complement anaphylatoxins and their biological responses. In: Frank, M., Volanakis, J. (Eds.), Human Complement System in Health and Disease. Marcel Dekker, New York, pp. 241-284.
22. Erdos, E., 1979. Handbook of experimental pharmacology. In: Erdos, E. (Ed.), Bradykinin, Kallidin and Kallikrein, vol. 25. Springer, Heidelberg, pp. 427-487.
23. Erdos E.G., Sloane E.M. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 11:1962;562-585.
24. Fischer M.B., Prodeus A.P., Nicholson-Weller A., Ma M., Murrow J., Reid R.R., Warren H.B., Lage A.L., Moore F.D. Jr., Rosen F.S., Carroll M.C. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J. Immunol. 159:1997;976-982.
25. Gebhard W., Schube M., Eulitz M. cDNA cloning and complete primary structure of the small, active subunit of human carboxypeptidase N (kininase 1). Eur. J. Biochem. 178:1989;603-607.
26. Gomis-Ruth F.X., Companys V., Qian Y., Fricker L.D., Vendrell J., Aviles F.X., Coll M. Crystal structure of avian carboxypeptidase D domain II: a prototype for the regulatory metallocarboxypeptidase subfamily. EMBO J. 18:1999;5817-5826.
27. Grimwood B.G., Plummer T.H. Jr., Tarentino A.L. Characterization of the carboxypeptidase N secreted by Hep G2 cells. J. Biol. Chem. 263:1988;14397- 14401.
28. Hadkar V., Skidgel R.A. Carboxypeptidase D is up-regulated in raw 264.7 macrophages and stimulates nitric oxide synthesis by cells in arginine-free medium. Mol. Pharmacol. 59:2001;1324-1332.
29. Hashimoto H., Abendschein D.R., Strauss A.W., Sobel B.E. Early detection of myocardial infarction in conscious dogs by analysis of plasma MM creatine kinase isoforms. Circulation. 71:1985;363-369.
30. Haviland D.L., McCoy R.L., Whitehead W.T., Akama H., Molmenti E.P., Brown A., Haviland J.C., Parks W.C., Perlmutter D.H., Wetsel R.A. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J. Immunol. 154:1995;1861-1869.
31. Hendriks D., Soons J., Scharpe S., Wevers R., van Sande M., Holmquist B. Identification of the carboxypeptidase responsible for the post-synthetic modification of creatine kinase in human serum. Clin. Chim. Acta. 172:1988;253-260.
32. Hendriks D., Scharpe S., van Sande M., Lommaert M.P. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J. Clin. Chem. Clin. Biochem. 27:1989;277-285.
33. Hess J.F., Borkowski J.A., Young G.S., Strader C.D., Ransom R.W. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem. Biophys. Res. Commun. 184:1992;260-268.
34. Hess J.F., Borkowski J.A., Macneil T., Stonesifer G.Y., Fraher J., Strader C.D., Ransom R.W. Differential pharmacology of cloned human and mouse B2 bradykinin receptors. Mol. Pharmacol. 45:1994;1-8.
35. Huey R., Bloor C.M., Kawahara M.S., Hugli T. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). Am. J. Pathol. 112:1983;48-60.
36. Jaffe A.S., Serota H., Grace A., Sobel B.E. Diagnostic changes in plasma creatine kinase isoforms early after the onset of acute myocardial infarction. Circulation. 74:1986;105-109.
37. Jung Y.K., Kunczt C.J., Pearson R.K., Dixon J.E., Fricker L.D. Structural characterization of the rat carboxypeptidase E gene. Mol. Endocrinol. 5:1991;1257-1268.
38. Kalant D., Cain S.A., Maslowska M., Sniderman A.D., Cianflone K., Mmonk P.N. The chemoattractant receptor-like protein C5L2 binds the C3a desArg77/acylation stimulating protein. J. Biol. Chem. 278:2003;11123-11129.
39. Kildsgaard J., Hollmann T.J., Matthews K.W., Bian K., Murad F., Wetsel R.A. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J. Immunol. 165:2000;5406-5409.
40. Landschulz W.H., Johnson P.F., McKnight S.L. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science. 240:1988;1759-1764.
41. Levin Y., Skidgel R.A., Erdos E.G. Isolation and characterization of the subunits of human plasma carboxypeptidase N (kininase i). Proc. Natl. Acad. Sci. U.S.A. 79:1982;4618-4622.
42. Li J., Rehli M., Timblin B., Tan F., Krause S.W., Skidgel R.A. Structure of the human carboxypeptidase M gene. Identification of a proximal GC-rich promoter and a unique distal promoter that consists of repetitive elements. Gene. 284:2002;189-202.
43. Mathews K.P. Deficiencies in regulator proteins 4. Anaphylatoxin inactivator. Prog. Allergy. 39:1986;344-351.
44. Mathews K.P., Pan P.M., Gardner N.J., Hugli T.E. Familial carboxypeptidase N deficiency. Ann. Int. Med. 93:1980;443-445.
45. Mathews K.P., Curd J.G., Hugli T.E. Decreased synthesis of serum carboxypeptidase N (SCPN) in familial SCPN deficiency. J. Clin. Immunol. 6:1986;87-91.
46. Matthews K.W., Wetsel R.A. Characterization of mouse carboxypeptidase N small active subunit gene structure. J. Immunol. 166:2001;6196-6202.
47. McGwire G.B., Becker R.P., Skidgel R.A. Carboxypeptidase M, a glycosylphosphatidylinositol-anchored protein, is localized on both the apical and basolateral domains of polarized Madin-Darby canine kidney cells. J. Biol. Chem. 274:1999;31632-31640.
48. Michelutti L., Falter H., Certossi S., Marcotte B., Mazzuchin A. Isolation and purification of creatine kinase conversion factor from human serum and its identification as carboxypeptidase N. Clin. Biochem. 20:1987;21-29.
49. Moncada S., Higgs E.A. Molecular mechanisms and therapeutic strategies related to nitric oxide. Faseb. J. 9:1995;1319-1330.
50. Morelli R.L., Carlson C.J., Emilson B., Abendschein D.R., Rapaport E. Serum creatine kinase MM isoenzyme sub-bands after acute myocardial infarction in man. Circulation. 67:1983;1283-1289.
51. Nagae A., Abe M., Becker R.P., Deddish P.A., Skidgel R.A., Erdos E.G. High concentration of carboxypeptidase M in lungs: presence of the enzyme in alveolar type I cells. Am. J. Respir. Cell. Mol. Biol. 9:1993;221-229.
52. Nagashima M., Yin Z.F., Zhao L., White K., Zhu Y., Lasky N., Halks-Miller M., Broze G.J. Jr., Fay W.P., Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J. Clin. Invest. 109:2002;101-110.
53. Naggert J.K., Fricker L.D., Varlamov O., Nishina P.M., Rouille Y., Steiner D.F., Carroll R.J., Paigen B.J., Leiter E.H. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat. Genet. 10:1995;135-142.
54. Okinaga S., Slattery D., Humbles A., Zsengeller Z., Morteau O., Kinrade M.B., Brodbeck R.M., Krause J.E., Choe H.R., Gerard N.P., Gerard C. C5L2, a nonsignaling C5A binding protein. Biochemistry. 42:2003;9406-9415.
55. Oshima G., Kato J., Erdos E.G. Plasma carboxypeptidase N, subunits and characteristics. Arch. Biochem. Biophys. 170:1975;132-138.
56. Pineau P., Marchio A., Terris B., Mattei M.G., Tu Z.X., Tiollais P., Dejean A. A t(38) chromosomal translocation associated with hepatitis B virus integration involves the carboxypeptidase N locus. J. Virol. 70:1996;7280-7284.
57. Plummer T.H. Jr., Hurwitz M.Y. Human plasma carboxypeptidase N. Isolation and characterization. J. Biol. Chem. 253:1978;3907-3912.
58. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32:1980;1-46.
59. Rehli M., Krause S.W., Kreutz M., Andreesen R. Carboxypeptidase M is identical to the MAX.1 antigen and its expression is associated with monocyte to macrophage differentiation. J. Biol. Chem. 270:1995;15644-15649.
60. Rehli M., Krause S.W., Andreesen R. The membrane-bound ectopeptidase CPM as a marker of macrophage maturation in vitro and in vivo. Adv. Exp. Med. Biol. 477:2000;205-216.
61. Reynolds D.S., Stevens R.L., Gurley D.S., Lane W.S., Austen K.F., Serafin W.E. Isolation and molecular cloning of mast cell carboxypeptidase A. A novel member of the carboxypeptidase gene family. J. Biol. Chem. 264:1989;20094-20099.
62. Riley D.A., Tan F., Miletich D.J., Skidgel R.A. Chromosomal localization of the genes for human carboxypeptidase D (CPD) and the active 50-kDa subunit of human carboxypeptidase N (CPN1). Genomics. 50:1998;105-108.
63. Sato T., Miwa T., Akatsu H., Matsukawa N., Obata K., Okada N., Campbell W., Okada H. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J. Immunol. 165:2000;1053-1058.
64. Shinohara T., Sakurada C., Suzuki T., Takeuchi O., Campbell W., Ikeda S., Okada N., Okada H. Pro-carboxypeptidase R cleaves bradykinin following activation. Int. Arch. Allergy Immunol. 103:1994;400-404.
65. Skidgel, R.A., 1996. Structure and function of mammalian zinc carboxypeptidase. In: Hooper, N.M. (Ed.), Zinc Metalloprotease in Health and Disease. Taylor & Francis, London, pp. 241-283.
66. Skidgel R.A., Johnson A.R., Erdos E.G. Hydrolysis of opioid hexapeptides by carboxypeptidase N. Presence of carboxypeptidase in cell membranes. Biochem. Pharmacol. 33:1984;3471-3478.
67. Swaisgood C.M., Schmitt D., Eaton D., Plow E.F. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J. Clin. Invest. 110:2002;1275-1282.
68. Tan A.K., Eaton D.L. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 34:1995;5811-5816.
69. Tan F., Weerasinghe D.K., Skidgel R.A., Tamei H., Kaul R.K., Roninson I.B., Schilling J.W., Erdos E.G. The deduced protein sequence of the human carboxypeptidase N high molecular weight subunit reveals the presence of leucine-rich tandem repeats. J. Biol. Chem. 265:1990;13-19.
70. Timblin B., Rehli M., Skidgel R.A. Structural characterization of the human carboxypeptidase D gene and its promoter. Int. Immunopharmacol. 2:2002;1907-1917.
71. Wetsel R.A. Expression of the complement C5a anaphylatoxin receptor (C5aR) on non-myeloid cells. Immunol. Lett. 44:1995;183-187.
72. Wetsel, R.A., Kildsgaard, J., Haviland, D.L., 2000. Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation. In: Lambris, J.D., Holers, V.M. (Eds.), Therapeutic Interventions in the Complement System. Humana Press, Totowa, NJ, pp. 113-153.
73. Zahedi R., Braun M., Wetsel R.A., Ault B.H., Khan A., Welch T.R., Frenzke M., Davis A.E. The C5a receptor is expressed by human renal proximal tubular epithelial cells. Clin. Exp. Immunol. 121:2000;226-233.